<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809639</url>
  </required_header>
  <id_info>
    <org_study_id>WFU Procuss</org_study_id>
    <nct_id>NCT01809639</nct_id>
  </id_info>
  <brief_title>Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion</brief_title>
  <official_title>Micronized Oral Progesterone and Effect on Time Symptomatic From Concussion: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Medical Society for Sports Medicine (AMSSM) Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concussions are a common injury among athletes in the United States. The annual incidence of
      sports and recreational related traumatic brain injuries in the United States is 1.6 to 3.8
      million, and the likelihood of an athlete in a contact sport experiencing a concussion is as
      high as 20 percent per season. Even mild traumatic brain injury, including concussion, can
      cause long-term cognitive problems that affect a person's ability to perform daily activities
      and to return to school or work. Far more concerning is the mounting body of evidence that
      concussions are not just transient injuries - but have cumulative effects. It has been well
      established in animal models that progesterone has neuroprotective benefits. Animal studies
      using progesterone for acute post-injury treatment have demonstrated reduced cerebral edema,
      reduced neuro-inflammatory markers, decreased neuronal loss, and improved behavioral
      outcomes. To date, there have been no studies to assess whether or not progesterone will be
      effective for the treatment of concussions. This double-blind placebo controlled trial will
      assess the ability of 5 days of oral micronized progesterone (Prometrium®) to shorten the
      duration of symptoms of an athlete diagnosed with concussion. The investigators hypothesize
      that athletes treated with progesterone will have faster resolution of their concussive
      symptoms. The investigators believe this study may be the first clinical trial to show an
      effective treatment for concussion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time (in Days) That a Patient Reports Symptoms From Their Concussion.</measure>
    <time_frame>From date of injury until date asymptomatic, assessed up to 24 months</time_frame>
    <description>The total time that a patient reports symptoms will be assessed. Once the patient reports that they are asymptomatic, the patient will repeat the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) test to determine if the patient's score has returned to baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Concussion</condition>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg of oral micronized progesterone (Prometrium®) on days one, two, and three then 200mg on days four and five</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <arm_group_label>Progesterone</arm_group_label>
    <other_name>Prometrium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Standard placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with a concussion

          -  A 18 years or older

          -  Diagnosis &lt; 24 hours from injury

          -  Consent obtained prior to concussion

        Exclusion Criteria:

          -  Pregnant

          -  Active breast or reproductive organ cancers

          -  Allergy to peanuts

          -  History of or current thrombophlebitis or venous thromboembolic disorder

          -  Females taking birth control

          -  Known hypersensitivity or prior adverse reaction to progesterone

          -  Known liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher M Miles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John A Lucas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2013</study_first_submitted>
  <study_first_submitted_qc>March 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2013</study_first_posted>
  <results_first_submitted>April 28, 2016</results_first_submitted>
  <results_first_submitted_qc>June 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2016</results_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Concussion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Progesterone</title>
          <description>400mg of oral micronized progesterone (Prometrium®) on days one, two, and three then 200mg on days four and five
Progesterone</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Standard placebo for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Progesterone</title>
          <description>400mg of oral micronized progesterone (Prometrium®) on days one, two, and three then 200mg on days four and five
Progesterone</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Standard placebo for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time (in Days) That a Patient Reports Symptoms From Their Concussion.</title>
        <description>The total time that a patient reports symptoms will be assessed. Once the patient reports that they are asymptomatic, the patient will repeat the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) test to determine if the patient's score has returned to baseline.</description>
        <time_frame>From date of injury until date asymptomatic, assessed up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>400mg of oral micronized progesterone (Prometrium®) on days one, two, and three then 200mg on days four and five
Progesterone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Standard placebo for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time (in Days) That a Patient Reports Symptoms From Their Concussion.</title>
          <description>The total time that a patient reports symptoms will be assessed. Once the patient reports that they are asymptomatic, the patient will repeat the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) test to determine if the patient's score has returned to baseline.</description>
          <units>Days Symptomatic</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="8.64"/>
                    <measurement group_id="O2" value="4.5" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.42</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Progesterone</title>
          <description>400mg of oral micronized progesterone (Prometrium®) on days one, two, and three then 200mg on days four and five
Progesterone</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Standard placebo for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Lucas</name_or_title>
      <organization>Spartanburg Regional Healthcare System</organization>
      <phone>423-309-5646</phone>
      <email>jlucas@srhs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

